Functional analysis of the gene expression profiles of colorectal cancer cell lines in relation to oxaliplatin and cisplatin cytotoxicity

Oncology Reports

Volumn 17, Issue 5, 2007, Pages 1213-1221

  Meynard, Delphine ^a   Le Morvan, Valérie ^a   Bonnet, Jacques ^a   Robert, Jacques ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Colorectal cancer; Gene expression profiling; In vitro cytotoxicity; Platinum complexes

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; OXALIPLATIN; PLATINUM COMPLEX;

ARTICLE; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL TUMOR; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; COLORECTAL NEOPLASMS; GENE EXPRESSION PROFILING; HCT116 CELLS; HT29 CELLS; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS;

EID: 34548557199     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.5.1213     Document Type: Article

References (20)

1. Rosenberg B: Fundamental studies with cisplatin. Cancer 55: 2303-2316, 1985.
2. Hamilton TC, O'Dwyer PJ and Ozols RF: Platinum analogues in preclinical and clinical development. Curr Opin Oncol 5: 1010-1016, 1993. (Pubitemid 24007512)
3. Misset JL, Bleiberg H, Sutherland W, Bekradda M and Cvitkovic E: Oxaliplatin clinical activity: a review. Crit Rev Oncol Hematol 35: 75-93, 2000. (Pubitemid 30599431)
4. Kemeny N, Israel K, Niedzwiecki D, et al: Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 8: 313-318, 1990. (Pubitemid 20056563)
5. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K and Fojo T: Oxaliplatin, tetraplatin, cisplatin and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute anticancer drug screen panel. Biochem Pharmacol 52: 1855-1865, 1990.
6. Vekris A, Meynard D, Haaz MC, Bayssas M, Bonnet J and Robert J: Determinants of the clinical activity of platinum compounds: the contribution of in silico research. Cancer Res 64: 356-362, 2004. (Pubitemid 38114118)
7. Di Francesco AM, Ruggiero A and Riccardi R: Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci 59: 1914-1927, 2002. (Pubitemid 36015864)
8. Raymond E, Faivre S, Woynarowski JM and Chaney SG: Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 25 (suppl 5): 4-12, 1998. (Pubitemid 28248696)
9. Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer 34: 1534-1542, 1998.
10. Niedner H, Christen R, Lin X, Kondo A and Howell SB: Identification of genes that mediate sensitivity to cisplatin. Mol Pharmacol 60: 1153-1160, 2001. (Pubitemid 33144883)
11. Komatsu M, Sumizawa T, Mutoh M, et al: Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res 60: 1312-1316, 2000. (Pubitemid 30152000)
12. Schenk PW, Boersma AW, Brandsma JA, et al: SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer Res 61: 6982-6986, 2001. (Pubitemid 32946481)
13. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S and Pendyala L: In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48: 398-406, 2001. (Pubitemid 33027997)
14. Arnould S, Hennebelle I, Canal P, Bugat R and Guichard S: Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer 39: 112-119, 2003. (Pubitemid 36005433)
15. Samimi G, Manorek G, Castel R, et al: cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 55: 1-11, 2005. (Pubitemid 40064490)
16. Arango D, Wilson AJ, Shi Q, et al: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer 91: 1931-1946, 2004. (Pubitemid 40065523)
17. Shirota Y, Stoehlmacher J, Brabender J, et al: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304, 2001. (Pubitemid 33096777)
18. Brown JM and Wouters BG: Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Res 59: 1391-1399, 1999. (Pubitemid 29160097)
19. Chaney S: The chemistry and biology of platinum complexes with the 1,2-diaminocyclohexane carrier ligand. Int J Oncol 6: 1291-1305, 1995.
20. Dukan S, Farewell A, Ballesteros M, Taddei F, Radman M and Nystrom T: Protein oxidation in response to increased transcriptional or translational errors. Proc Natl Acad Sci USA 97: 5746-5749, 2000. (Pubitemid 30367469)